一氧化氮在新型冠状病毒感染中的应用
Application of nitric oxide in corona virus disease 2019
Received date: 2023-10-12
Online published: 2024-04-28
新型冠状病毒感染（coronavirus disease 2019, COVID-19）的发生造成了世界范围的医疗危机和卫生资源紧张。一氧化氮（nitric oxide， NO）在2003年严重急性呼吸综合征（severe acute respiratory syndrome， SARS）期间被证明可以改善氧合，降低肺动脉压力，减少无创通气的需求。SARS冠状病毒（SARS coronavirus， SARS-CoV）与SARS-CoV-2遗传结构和病理特征具有重叠性，并且NO具有抗病毒、舒张血管、抗凝、抗炎作用。本文拟对NO在COVID-19中的应用展开综述，以期为后续COVID-19患者的治疗提供思路。
关键词： 一氧化氮; 新型冠状病毒感染; 急性呼吸综合征冠状病毒-2; 血管舒张; 抗病毒
王亚婷, 贺春伟, 付紫玉, 王慧, 马德东 . 一氧化氮在新型冠状病毒感染中的应用[J]. 内科理论与实践, 2024 , 19(01) : 82 -87 . DOI: 10.16138/j.1673-6087.2024.01.15
The outbreak of coronavirus disease 2019 (COVID-19) has caused a worldwide medical crisis and strained health resources. Nitric oxide (NO) is shown to improve oxygenation, reduce pulmonary artery pressure, and reduce the need for noninvasive ventilation during severe acute respiratory syndrome (SARS) in 2003. SARS coronavirus (SARS-CoV) and SARS-CoV-2 have overlapping genetic structure and pathological characteristics, and NO has antiviral, vasodilator, anticoagulant and anti-inflammatory effects. This article reviewed the application of NO in COVID-19 patients, to provide the treatment strategy for new COVID-19 patients.
| [1] | 中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中华流行病学杂志, 2020, 41(2): 139-144. |
| [2] | Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733. |
| [3] | Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults[J]. N Engl J Med, 2005, 353(25):2683-2695. |
| [4] | Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine[J]. Nature, 1980, 288(5789):373-376. |
| [5] | Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine[J]. Nature, 1988, 333(6174) :664-666. |
| [6] | 罗金梅, 肖毅. 一氧化氮史话[J]. 中华结核和呼吸杂志, 2011, 34(12): 913. |
| [7] | Gebistorf F, Karam O, Wetterslev J, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults[J]. Cochrane Database Syst Rev, 2016, 2016(6):CD002787. |
| [8] | Yu B, Ichinose F, Bloch DB, et al. Inhaled nitric oxide[J]. Br J Pharmacol, 2019, 176(2):246-255. |
| [9] | Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome[J]. Clin Infect Dis, 2004, 39(10):1531-1535. |
| [10] | Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus[J]. Lancet, 2020, 395(10224):565-574. |
| [11] | Ignarro LJ. Nitric oxide is not just blowing in the wind[J]. Br J Pharmacol, 2019, 176(2): 131-134. |
| [12] | Moncada S, Higgs A. The L-arginine-nitric oxide pathway[J]. N Engl J Med, 1993, 329(27):2002-2012. |
| [13] | Bhatraju P, Crawford J, Hall M, et al. Inhaled nitric oxide: Current clinical concepts[J]. Nitric Oxide, 2015, 50:114-128. |
| [14] | Emrani J, Ahmed M, Jeffers-Francis L, et al. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment[J]. Int J Biol Macromol, 2021, 193 Pt B:1249-1273. |
| [15] | Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273. |
| [16] | Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2[J]. Cell, 2020, 181(4):894-904. |
| [17] | Keyaerts E, Vijgen L, Chen L, et al. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound[J]. Int J Infect Dis, 2004, 8(4):223-226. |
| [18] | Akerstr?m S, Mousavi-Jazi M, Klingstr?m J, et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus[J]. J Virol, 2005, 79(3):1966-1969. |
| [19] | Akerstr?m S, Gunalan V, Keng CT, et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected[J]. Virology, 2009, 395(1):1-9. |
| [20] | Akaberi D, Krambrich J, Ling J, et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro[J]. Redox Biol, 2020, 37:101734. |
| [21] | Michel JB. Nitric oxide (NO) and vasomotor tone[J]. Pathol Biol (Paris), 1998, 46(3): 181-189. |
| [22] | Gattinoni L, Coppola S, Cressoni M, et al. COVID-19 does not lead to a “typical” acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2020, 201(10):1299-1300. |
| [23] | Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069. |
| [24] | Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. |
| [25] | Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?[J]. Intensive Care Med, 2020, 46(6):1099-1102. |
| [26] | Lang M, Som A, Mendoza DP, et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT[J]. Lancet Infect Dis, 2020, 20(12):1365-1366. |
| [27] | Cyr AR, Huckaby LV, Shiva SS, et al. Nitric oxide and endothelial dysfunction[J]. Crit Care Clin, 2020, 36(2):307-321. |
| [28] | Green SJ. COVID-19 accelerates endothelial dysfunction and nitric oxide deficiency[J]. Microbes Infect, 2020, 22(4-5):149-150. |
| [29] | Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome[J]. Lancet, 2003, 361(9371):1773-1778. |
| [30] | Ng KH, Wu AK, Cheng VC, et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome[J]. Postgrad Med J, 2005, 81(956):e3. |
| [31] | Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4[J]. J Infect Dis, 2016, 213(5):712-722. |
| [32] | Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19[J]. Blood, 2020, 136(11): 1330-1341. |
| [33] | Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720. |
| [34] | Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19[J]. N Engl J Med, 2020, 383(2):120-128. |
| [35] | Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation[J]. Blood, 2020, 135(23): 2033-2040. |
| [36] | Kuprash DV, Nedospasov SA. Molecular and cellular mechanisms of inflammation[J]. Biochemistry (Mosc), 2016, 81(11):1237-1239. |
| [37] | Korhonen R, Lahti A, Kankaanranta H, et al. Nitric oxide production and signaling in inflammation[J]. Curr Drug Targets Inflamm Allergy, 2005, 4(4):471-479. |
| [38] | Cinelli MA, Do HT, Miley GP, et al. Inducible nitric oxide synthase: regulation, structure, and inhibition[J]. Med Res Rev, 2020, 40(1):158-189. |
| [39] | Darif D, Hammi I, Kihel A, et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong?[J]. Microb Pathog, 2021, 153:104799. |
| [40] | Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell in-fection and endotheliitis in COVID - 19[J]. Lancet, 2020, 395(10234):1417-1418. |
| [41] | Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation[J]. J Physiol Pharmacol, 2003, 54(4):469-487. |
| [42] | Parikh R, Wilson C, Weinberg J, et al. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients[J]. Ther Adv Respir Dis, 2020, 14:1753466620933510. |
| [43] | Safaee Fakhr B, Di Fenza R, Gianni S, et al. Inhaled high dose nitric oxide is a safe and effective respiratory treat-ment in spontaneous breathing hospitalized patients with COVID-19 pneumonia[J]. Nitric Oxide, 2021, 116: 7-13. |
| [44] | Winchester S, John S, Jabbar K, et al. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection[J]. J Infect, 2021, 83(2):237-279. |
| [45] | Martel J, Ko YF, Young JD, et al. Could nasal nitric ox-ide help to mitigate the severity of COVID - 19?[J]. Mi-crobes Infect, 2020, 22(4-5):168-171. |
| [46] | ANON. Coronavirus disease 2019 (COVID-19) treatment guidelines[EB/OL]. Bethesda (MD): National Institutes of Health (US). 2021. https://www.ncbi.nlm.nih.gov/books/NBK570371/. |
| [47] | Ferrari M, Santini A, Protti A, et al. Inhaled nitric oxide in mechanically ventilated patients with COVID-19[J]. J Crit Care, 2020, 60:159-160. |
| [48] | Abou-Arab O, Huette P, Debouvries F, et al. Inhaled ni-tric oxide for critically ill Covid-19 patients[J]. Crit Care, 2020, 24(1):645. |
| [49] | Lotz C, Muellenbach RM, Meybohm P, et al. Effects of inhaled nitric oxide in COVID-19-induced ARDS — is it worthwhile?[J]. Acta Anaesthesiol Scand, 2021, 65(5):629-632. |
| [50] | Robba C, Ball L, Battaglini D, et al. Early effects of venti-latory rescue therapies on systemic and cerebral oxygen-ation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome[J]. Crit Care, 2021, 25(1):111. |
| [51] | Longobardo A, Montanari C, Shulman R, et al. Inhaled ni-tric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome[J]. Br J An-aesth, 2021, 126(1):e44-e46. |
| [52] | Di Fenza R, Shetty NS, Gianni S, et al. High - dose in-haled nitric oxide in acute hypoxemic respiratory failure due to COVID-19[J]. Am J Respir Crit Care Med, 2023, 208(12):1293-1304. |
| [53] | 周永芳, 付江泉, 董文涛, 等. 吸入一氧化氮治疗重及危重型新型冠状病毒感染的疗效与安全性的 Meta 分析[J]. 结核与肺部疾病杂志, 2023, 4(1): 33-40. |
| [54] | Tavazzi G, Pozzi M, Mongodi S, et al. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia[J]. Crit Care, 2020, 24(1):508. |
| [55] | Garfield B, McFadyen C, Briar C, et al. Potential for per-sonalised application of inhaled nitric oxide in COVID-19 pneumonia[J]. Br J Anaesth, 2021, 126(2):e72-e75. |
| [56] | Feng WX, Yang Y, Wen J, et al. Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension[J]. ESC Heart Fail, 2021, 8(1):714-718. |
| [57] | Vives M, Gascó I, Pla G, et al. Inhaled nitric oxide in acute severe pulmonary hypertension and severe acute re-spiratory distress syndrome secondary to COVID-19 pneumonia[J]. Am J Case Rep, 2022, 23:e937147. |
| [58] | Zamanian RT, Pollack CV Jr, Gentile MA, et al. Outpa-tient inhaled nitric oxide in a patient with vasoreactive id-iopathic pulmonary arterial hypertension and COVID-19 infection[J]. Am J Respir Crit Care Med, 2020, 202(1):130-132. |
| [59] | Zambrano LD, Ellington S, Strid P, et al. Update: charac-teristics of symptomatic women of reproductive age with laboratory - confirmed SARS - CoV - 2 infection by preg-nancy status - United States, January 22-October 3, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(44):1641-1647. |
| [60] | Kasehagen L, Byers P, Taylor K, et al. COVID-19-associ-ated deaths after SARS - CoV - 2 infection during preg-nancy - mississippi, March 1, 2020 - October 6, 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(47):1646-1648. |
| [61] | Safaee FB, Wiegand SB, Pinciroli R, et al. High concen-trations of nitric oxide inhalation therapy in pregnant pa-tients with severe coronavirus disease 2019 (COVID-19)[J]. Obstet Gynecol, 2020, 136(6):1109-1113. |
| [62] | Valsecchi C, Winterton D, Safaee Fakhr B, et al. High-dose inhaled nitric oxide for the treatment of spontane-ously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia[J]. Obstet Gynecol, 2022, 140(2):195-203. |
| [63] | Hedenstierna G, Chen L, Hedenstierna M, et al. Nitric ox-ide dosed in short bursts at high concentrations may pro-tect against COVID 19[J]. Nitric Oxide, 2020, 103:1-3. |
| [64] | Gianni S, Fakhr BS, Morais CC A, et al. Nitric oxide gas inhalation to prevent COVID-2019 in healthcare provid-ers[J]. medRxiv, 2020:20054544. |
/
| 〈 |
|
〉 |
